The RAS is an endocrine system that plays a central role in cardiovascular and renal physiology through regulation of blood pressure and sodium balance. Deregulated RAS may contribute to pathogenesis such as atherosclerosis, ischemic disease, hypertension, and heart failure. The physiological effects of the RAS are mediated by bioactive angiotensin peptides generated by enzymatic cascades and released in the systemic circulation as well as locally in various tissues ([@B14]). The "classical RAS" produces the AngII octapeptide through cleavage of inactive AngI by angiotensin converting enzyme (ACE), whereas the "alternative RAS axis" ([@B63]) produces Ang1--7 by subsequent cleavage of AngII by the ACE homolog ACE2 (**Figure [1](#F1){ref-type="fig"}**). All Angiotensin peptides bind to GPCRs, namely AT1, and AT2 receptors for AngII and Mas receptor for Ang(1--7), but activate distinct signaling pathways leading to different and often opposite cellular effects (**Figure [1](#F1){ref-type="fig"}**). It is generally accepted that the classical ACE/AngII/AT1 axis promotes most of the RAS actions on cardiovascular, renal, and cerebral functions, and that these effects are counteracted by activation of the AT2 receptor ([@B52]; [@B40]) and by the "protective" ACE2/Ang(1--7)/Mas axis ([@B63]).

![**Schematic representation of the classical and alternative renin-angiotensin system (RAS) pathways.** Available agonists and antagonists are indicated for each angiotensin G-protein coupled receptor (GPCR): AT1, AT2, and Mas. Available ARBs (AT1 receptor blockers) are Losartan, Candesartan, Valsartan, Irbesartan, Telmisartan, Eprosartan, Olmesartan, and Azilsartan.](fphar-06-00024-g001){#F1}

Beyond cardiovascular functions, several studies have pointed out a role for RAS components in solid tumors including breast tumors (reviewed in [@B28]). Breast cancer is the major cause of death by cancer in women worldwide and the occurrence of distant metastasis is a critical event that limits patients survival. While targeted molecular therapies have considerably improved the management of primary breast tumors, these remain poorly effective for the treatment of metastases. The identification of molecular agents that may contribute to breast cancer progression is therefore essential for future development of new therapeutic strategies. Targeting GPCRs is of particular interest because of the availability of specific agonists and antagonists of the receptors. In addition, their cell surface location makes them suitable for blockade by humanized antibodies, a strategy successfully developed for HER2+ breast tumors with trastuzumab (Herceptin®). Of interest, most components of the RAS are locally expressed in breast tumors and microenvironment (macrophages and vascular cells; [@B32]; [@B15]; [@B70]; [@B30]; [@B28]) pointing out angiotensin receptors as potential targets in breast cancer.

In this review, we summarize current knowledge on angiotensin receptors (AT1, AT2, and Mas) in breast cancer, and discuss the potential use of angiotensin receptor agonists and antagonists in malignancy.

ANGIOTENSIN RECEPTORS IN CANCER
===============================

G-protein coupled receptors (GPCRs) of the renin-angiotensin system (RAS) system are activated by angiotensin peptides which are produced by angiotensin converting enzyme (ACE). ACE inhibitors (ACEi) have been assessed in cancer to characterize angiotensin functions in tumor growth, angiogenesis, and metastasis, and were shown to inhibit cell proliferation and tumor progression in several cancer models (reviewed in [@B60]). However, ACEi prevent production of both angiotensin II (AngII) and Ang1--7, thus preventing activation of all angiotensin receptors. Targeting specific angiotensin receptors using selective agonists or antagonists is warranted in order to validate their use to block tumor progression.

AT1 RECEPTOR
------------

The AT1 receptor is ubiquitously expressed in human tissues and is responsible for most of the AngII actions. AT1 activation by AngII triggers a large number of intracellular effectors leading to modulation of various cell processes, including proliferation, migration, angiogenesis, and inflammation, which are closely associated with tumor progression ([@B18]). Angiotensin receptor blockers (ARBs), such as losartan, candesartan, or valsartan, have been assayed both in cancer cells and in mouse experimental models to characterize AngII/AT1 functions in tumor growth, angiogenesis, and metastasis ([@B28]). Evidence for a role of AT1 receptor on cancer cell metastasis came from *in vivo* studies of lung models of metastasis. After injection of cancer cells into the tail vein of mice, oral administration of candesartan led to a strong reduction of lung metastasis ([@B44]). However, in this study it was not clear whether ARBs act on tumor cells or on the stromal microenvironment. The role of AT1 in the tumor microenvironment has been investigated by comparing the growth and vascularization of tumors injected subcutaneously into wild type (WT) or AT1 knockout mice ([@B22]; [@B25]; [@B31]). Tumor growth and vascularization were strongly reduced in AT1 null mice indicating that the AT1 of host cells contributes to both tumor growth and angiogenesis. Of interest, AT1-dependent tumor growth involves an increase in VEGF synthesis, a well-known angiogenic factor ([@B25]). Furthermore, AT1 is highly expressed in the stromal tissue surrounding the tumors, in particular in tumor-associated macrophages (TAMs). Macrophage infiltration, as well as levels of TAMs-released VEGF, were strongly reduced in AT1 null mice, supporting the hypothesis that host AT1 might also participate in inflammation-related tumor angiogenesis to maintain tumor growth ([@B22]; [@B25]). In glial tumor patients, AT1 expression was associated with higher proliferation and vascular density and with reduced survival, indicating that AT1-expressing tumors are of poor prognosis ([@B3]).

AT2 RECEPTOR
------------

Angiotensin II also binds the AT2 receptor subtype but less is known about the functional consequence of AT2 receptor activation in cancer. *In vitro* studies indicate that over expression of AT2 reduces growth of lung adenocarcinomas cells ([@B49]). In agreement, exogenous administration of AT2 receptor by nanoparticles was found to significantly attenuate lung cancer growth in an orthotopic model of syngeneic tumor grafts ([@B34]). AT2 receptor activation using the agonist CGP42112A reduced colorectal liver metastasis ([@B1]), suggesting that AT2 activation might provide a novel strategy to inhibit tumor growth. Of interest, pancreatic cancer cells subcutaneously injected in AT2 knockout mice grew significantly faster than in WT mice, indicating that AT2 receptors present in the tumor microenvironment may prevent cancer progression ([@B21]). However, in some other studies, the development of chemically induced sarcoma was delayed in AT2 knockout mice, and AT2 blockade by AT2 antagonist PD123319 significantly reduced lung carcinomas xenografts growth ([@B12]). Thus, further studies are needed to elucidate AT2 functions in cancer.

Studies on AT2 receptor signaling allowed the identification of several AT2 interacting partners that are related to cancer ([@B59]). Among them, intracellular proteins of the ATIP family are encoded by candidate tumor suppressor gene *MTUS1*. *MTUS1* was shown to be down regulated in several solid tumors, including from pancreas ([@B65]), ovary ([@B50]), head-and-neck ([@B77]; [@B19]), colon ([@B78]), bladder ([@B76]), and breast ([@B58]), and ATIPs have been shown to display tumor suppressor effects ([@B65]; [@B58]). Investigating the functional relationship between AT2 and ATIPs might bring more clues toward understanding the effects of AT2 in cancer.

MAS RECEPTOR
------------

Angiotensins 1--7, the cleavage product of AngII by ACE2, belongs to the alternative RAS pathway and has protective effects on cardiovascular functions ([@B63]). Ang1--7 is an anti-proliferative and anti-angiogenic molecule that mediates its effects by binding to a unique GPCR, Mas ([@B64]; [@B47]).

The anti-proliferative and anti-angiogenic effects of the Ang1--7/Mas axis in cancer have been evaluated. *In vitro* studies on lung cancer cells confirmed the anti-proliferative function of Ang1--7 through Mas receptor ([@B26]). *In vivo* studies further indicated that administration of Ang1--7 reduces lung and prostate tumor xenografts ([@B26]; [@B42]; [@B35]), as well as prostate cancer metastasis ([@B36]). Of interest, Ang1--7 effect on tumor growth was associated with a strong effect on tumor microenvironment. Administration of Ang1--7 has been shown to act on endothelial cells to inhibit angiogenesis ([@B39]; [@B68]) but also on cancer-associated fibroblasts and osteoclasts to reduce breast cancer fibrosis and metastatic prostate tumor osteoclastogenesis, respectively ([@B13]; [@B36]). All *in vitro* effects of Ang1--7 are inhibited by the Mas receptor antagonist A779 ([@B39]), suggesting that Mas receptor mediates all protective functions of Ang1--7.

ANGIOTENSIN RECEPTORS IN BREAST CANCER
======================================

In breast tumors, most components of the RAS are expressed ([@B28]), suggesting that AngII may be locally produced. Studies from our group aimed at investigating the effect of AngII on breast cancer progression. To this end, metastatic breast cancer cells (D3H2LN) were exposed to AngII *in vitro* prior to injection into the blood flow of immunodeficient mice ([@B56]). Our studies revealed for the first time that AngII can directly act on breast cancer cells to promote cancer cell invasion and metastasis ([@B56]). Two major pathways activated by AngII were identified, that were related to cell proliferation and migration/invasion, respectively. These data highlight the importance of defining the role of angiotensin receptors in breast cancer as a first step toward blocking AngII production using ACEi or specifically targeting RAS GPCRs.

AT1
---

AT1 has been shown to be expressed both at mRNA and protein levels in normal and malignant breast tissues ([@B15]; [@B70]; [@B30]; **Table [1](#T1){ref-type="table"}**). Functional studies indicated that over expression of AT1 in breast cancer cells promotes cell invasion *in vitro* and tumor growth *in vivo* in absence of any stimulation by the AT1 agonist AngII ([@B53]). All these effects were dose-dependently inhibited by the AT1 antagonist losartan confirming the specific role of AT1. Blockade of AT1 by ARBs, such as losartan or candesartan, was shown to inhibit breast cancer cell proliferation *in vitro* and breast tumor xenograft growth in mice ([@B11]), suggesting that AT1 may be an interesting target against breast cancer. Interestingly, *in vitro* studies demonstrated that AT1 levels are increased in tamoxifen-resistant MCF7 cells as compared to sensitive counterparts, and that tamoxifen sensitivity was restored by blockade of AT1 by losartan ([@B45],[@B46]).

###### 

Renin-angiotensin system (RAS) G-protein coupled receptors (GPCRs) in breast cancer.

  Receptor   Detection method   *In vivo* model              Observation                                              Reference
  ---------- ------------------ ---------------------------- -------------------------------------------------------- -----------
  AT1        IHC/ISH                                         Increased in benign and malignant tumors                 [@B15]
             qPCR                                            Increased in carcinomas                                  [@B70]
             IHC                                             expressed in both ER+ and ER-                            [@B30]
             FISH/qPCR                                       overexpression in 10--20% breast carcinomas              [@B53]
                                MCF7 (subcutaneous)          Candesartan reduced tumor growth                         [@B11]
                                MCF7 (subcutaneous)          Losartan reduced growth of AGTR1-overexpressing tumors   [@B53]
  AT2        qPCR                                            Increased in carcinomas                                  [@B70]
             IHC/ISH                                         Increased in benign and malignant tumors                 [@B16]
  MAS        RT-PCR                                          detected in normal and malignant samples                 [@B43]
                                ZR75-1, BT474 (orthotopic)   Ang1--7 reduces tumor growth                             [@B13]

IHC: Immunohistochemistry; ISH:

In situ

hybridization, qPCR: quantitative PCR; FISH: Fluorescent

in situ

hybridization.

A large-scale meta-analysis performed on 31 breast cancer profiling datasets has revealed over expression of the AT1 receptor gene (AGTR1) in 10--20% of invasive breast tumors ([@B53]), all of which were estrogen receptor positive (ER+) and human epidermal receptor 2 (HER2)-negative. In another subset of 178 HER2-negative breast tumor patients, high AT1 expression was identified as a marker of resistance to anthracyclin-based neoadjuvant chemotherapy ([@B17]). Recent studies further suggested that high AT1 level may be a predictive marker of bevacizumab response in breast tumors ([@B62]; [@B61]). Of interest, bevacizumab-induced hypertension in breast cancer patients was also associated with better overall response to this anti-angiogenic therapy ([@B27]).

AT2
---

AT2 receptor levels have been shown to be markedly increased in breast tumors as compared to normal tissue ([@B16]; **Table [1](#T1){ref-type="table"}**) raising the question of the functional effect of AT2 over expression in breast cancer. To specifically examine this question, we generated a human metastatic breast cancer cell line stably expressing high amounts of human AT2 receptors at the plasma membrane and no detectable AT1 levels ([@B57]). This model allows the characterization of AT2 functions independently of those related to AT1 receptor activation, which is of great interest in the context of AT1 blockade by ARBs. It also offers a unique opportunity to evaluate the consequences of AT2 receptor activation and blockade on breast cancer proliferation, invasion, and migration, as well as on tumor growth and metastasis. This model is also suitable to investigate whether AT2 functions may rely on interaction with intracellular partners ([@B59]). ATIPs are interesting AT2 partners in the context of cancer, as ATIP1 has been shown to reduce proliferation of pancreatic cancer cells ([@B65]) whereas ATIP3, which is down-regulated in breast cancer, reduces tumor growth, and metastasis in experimental mice models ([@B58]). However, whether the consequence of AT2-ATIPs interaction is to promote or prevent breast cancer progression remains to be elucidated.

MAS
---

By quantitative RT-PCR, [@B29] found ACE2 expressed in most human cell lines and tissues examined including breast, indicating that Ang1--7 can be produced in most tissues. Preliminary studies detected Mas receptor at the mRNA level by RT-PCR in both benign and malignant breast tissues ([@B43]; **Table [1](#T1){ref-type="table"}**). These results need to be validated at the protein level but one can speculate that Mas/Ang1--7 axis is present and targetable in breast tumors. Of interest, in orthotopic breast cancer xenograft models, administration of Ang1--7 efficiently reduced tumor volume and weight ([@B13]) by acting both on tumor cells and microenvironment. Thus, Ang1--7 may be a useful therapeutic component against breast cancer.

TARGETING ANGIOTENSIN RECEPTORS IN BREAST CANCER
================================================

Preclinical studies thus provide a rationale for the potential use of either ARBs or Mas agonist to treat breast cancer patients. To go further, Ang1--7 and ARBs have been assessed in clinics to evaluate pharmacokinetics in phase I/II trial, and association with breast cancer risk, respectively.

AT1
---

Eight different ARBs (Losartan, Candesartan, Valsartan, Irbesartan, Telmisartan, Eprosartan, Olmesartan, and Azilsartan; **Figure [1](#F1){ref-type="fig"}**) are currently approved for the treatment of hypertension ([@B5]) and thus safely used in patients without major side effect, indicating that these ARBs may be reconsidered for the treatment of others pathologies including breast cancer. Several studies evaluated breast cancer risk in ARBs users. Although one study indicated that ARBs are associated with a modest increased risk of new cancer diagnosis ([@B66]), other groups rather reported that ARBs do not influence the risk of developing a cancer, including breast cancer ([@B38]; [@B24]; [@B2]; [@B4]; [@B6]; [@B37]). Several studies showed that there is no significant association between the use of ARBs and overall survival of breast cancer patients ([@B66]; [@B9]; [@B7]). Other analyses indicated that ARBs users with invasive breast cancer have a reduced risk of recurrence ([@B9], [@B8]; [@B41]), although in one study ARBs were not associated with breast cancer recurrence ([@B67]), an apparent discrepancy that may reflect variations in AT1 levels among different breast cancer populations examined.

AT2
---

Compound C21 is the only non-peptide orally active AT2 receptor agonist tested in several preclinical models with broad potential indication ([@B74]). C21 has been shown to have beneficial effects on blood pressure, cardiac, and kidney functions and inflammation ([@B69]; [@B40]), and its effects in cancer still need to be investigated. Other AT2 ligands are under preclinical development ([@B5]). In particular the AT2 agonist LP2 compound (Lanthio Pharma) is under evaluation in heart and lung injury ([@B75]). AT2 antagonists such as PD123319 and its orally active derivative EMA401 were also investigated. Of interest, the highly selective AT2 antagonist EMA401 is under development as a novel neuropathic pain therapeutic agent ([@B54]). Thus, tools to either block or activate the AT2 receptor (**Figure [1](#F1){ref-type="fig"}**) are under development but preclinical studies are still needed to elucidate AT2 functions in cancer and to adequately target this receptor, in particular in breast cancer.

MAS
---

Targeting Mas receptor is a promising therapeutic option. Ang1--7 was evaluated in phase I clinical study involving eighteen patients with advanced solid tumors from colon, lung, pancreas, prostate, and soft tissues ([@B48]). Only mild toxicity was observed for high doses of Ang1--7 administrated subcutaneously ([@B48]). Of interest, in this study Ang1--7 treatment led to clinical benefit for four patients. In a phase I/II clinical study, Ang1--7 was administered before and after chemotherapy in breast cancer patients with no dose-limiting toxicity ([@B55]). These clinical studies suggest that Ang1--7 may be used in patients without major side effect. To go further, new tools to target Mas receptor are under development. These include orally active Ang1--7 derivatives and new Mas agonists such as the peptidic compound CGEN-856 and the non-peptidic AVE-0991 compound (**Figure [1](#F1){ref-type="fig"}**; [@B5]; [@B23]). Of note, patents were developed for the use of Ang1--7 as anti-cancer and chemopreventive agents able to prevent and reduce cancer growth, including in breast cancer ([@B72]; [@B71]).

CONCLUSION
==========

Angiotensin GPCRs appear as good therapeutic targets expressed at the cell surface and thus easily targetable with pharmacological drugs or humanized blocking antibodies. ARBs are already widely used to treat hypertension and may be safely used in other therapeutic applications, such as breast cancer, in combination with standard treatments. Targeting angiotensin receptors may be promising in several aspects, since beneficial effects of ARBs and Ang1--7 were observed on both tumor cells and tumor microenvironment ([@B13]; [@B11]). ARBs and Ang1--7 were also shown to reduce collagen secretion and deposition ([@B13]; [@B20]), enhancing drug delivery and potentiating chemotherapy ([@B20]; [@B10]). These interesting results open the way to the use of ARBs/Ang1--7 in complement with chemotherapy to improve their efficiency. Of note, protective effects of ARBs in cancer may be potentiated by Mas activation, as suggested in studies of vascular remodeling ([@B33]). In addition, ARBs have been shown to reduce cardiotoxicity of anthracyclin-based chemotherapy of breast cancer ([@B73]), whereas Ang(1--7) reduces cytopenia of ovarian cancer patients treated with gemcitabine/platinum-based chemotherapy ([@B51]). Thus using ARBs or Ang1--7 combined with chemotherapy may constitute an interesting strategy to both increase drug efficiency and reduce its side effects.

Future studies should be designed to further evaluate angiotensin receptor levels in breast tumors, in an attempt to select a population of patients that express high levels of AT1 or Mas receptors and may thus benefit from GPCR-targeted therapy.
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